Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
Castle Biosciences (Nasdaq: CSTL) has been recognized in Newsweek's inaugural America's Greatest Companies 2025 list. The company, which specializes in innovative molecular testing for patient care, was selected among 650 U.S. companies based on four key criteria: financial strength, workforce dedication, innovation, and commitment to environmental sustainability and corporate ethics.
The evaluation process incorporated company reviews, SEC filings, USPTO data, and third-party sources to objectively assess corporate performance. CEO Derek Maetzold highlighted the company's 'people first' approach, emphasizing their focus on developing pioneering molecular tests and fostering an innovative corporate culture.
Castle Biosciences (Nasdaq: CSTL) è stata riconosciuta nella prima lista di Newsweek, America's Greatest Companies 2025. L’azienda, specializzata in test molecolari innovativi per la cura dei pazienti, è stata selezionata tra 650 aziende statunitensi in base a quattro criteri chiave: solidità finanziaria, impegno del personale, innovazione e impegno per la sostenibilità ambientale e l’etica aziendale.
Il processo di valutazione ha incluso revisioni aziendali, filing SEC, dati USPTO e fonti terze per valutare oggettivamente la performance aziendale. Il CEO Derek Maetzold ha sottolineato l’approccio «people first», evidenziando l’attenzione a sviluppare test molecolari all’avanguardia e a coltivare una cultura aziendale innovativa.
Castle Biosciences (Nasdaq: CSTL) ha sido reconocida en la lista inaugural de Newsweek, America's Greatest Companies 2025. La empresa, especializada en pruebas moleculares innovadoras para la atención al paciente, fue seleccionada entre 650 compañías de EE. UU. según cuatro criterios clave: solidez financiera, dedicación de la plantilla, innovación y compromiso con la sostenibilidad ambiental y la ética empresarial.
El proceso de evaluación incorporó revisiones de la empresa, presentaciones ante la SEC, datos de la USPTO y fuentes externas para evaluar objetivamente el rendimiento corporativo. El CEO Derek Maetzold destacó el enfoque de la compañía en las personas, subrayando su prioridad en desarrollar pruebas moleculares pioneras y fomentar una cultura corporativa innovadora.
Castle Biosciences(Nasdaq: CSTL)가 Newsweek의 첫 번째 America's Greatest Companies 2025에 선정되었습니다. 환자 치료를 위한 혁신적인 분자 검사에 전문화된 이 회사는 재무 건전성, 직무헌신도, 혁신성, 환경 지속 가능성 및 기업 윤리에 대한 네 가지 핵심 기준을 바탕으로 미국 내 650개 회사 중에서 선정되었습니다.
평가 과정에는 회사 검토, SEC 공시, USPTO 데이터 및 제3자 소스가 포함되어 기업 성과를 객관적으로 평가했습니다. CEO Derek Maetzold는 ‘사람이 먼저’ 접근 방식을 강조하며, 선도적인 분자 검사 개발과 혁신적인 기업 문화 조성에 초점을 두었다고 밝혔습니다.
Castle Biosciences (Nasdaq : CSTL) a été reconnue dans la première liste Newsweek, America’s Greatest Companies 2025. L’entreprise, spécialisée dans les tests moléculaires innovants pour les soins aux patients, a été sélectionnée parmi 650 entreprises américaines selon quatre critères clés : solidité financière, engagement de la main-d’œuvre, innovation et engagement envers la durabilité environnementale et l’éthique d’entreprise.
Le processus d’évaluation a intégré des examens d’entreprise, des dépôts SEC, des données USPTO et des sources externes pour évaluer objectivement la performance de l’entreprise. Le PDG Derek Maetzold a mis en avant l’approche « people first », soulignant leur concentration sur le développement de tests moléculaires pionniers et sur la promotion d’une culture d’entreprise innovante.
Castle Biosciences (Nasdaq: CSTL) wurde in Newsweeks erster America's Greatest Companies 2025-Liste anerkannt. Das Unternehmen, das sich auf innovative molekulare Tests für die Patientenversorgung spezialisiert hat, wurde aus 650 US-Unternehmen basierend auf vier Schlüsselkriterien ausgewählt: finanzielle Stärke, Einsatzbereitschaft der Belegschaft, Innovation sowie Engagement für Umweltverträglichkeit und Unternehmensethik.
Der Bewertungsprozess umfasste Unternehmensprüfungen, SEC-Anmeldungen, USPTO-Daten und Drittanbieterquellen, um die Unternehmensleistung objektiv zu bewerten. CEO Derek Maetzold hob den „People First“-Ansatz des Unternehmens hervor und betonte den Fokus auf die Entwicklung bahnbrechender molekularer Tests und die Förderung einer innovativen Unternehmenskultur.
Castle Biosciences (ناسداك: CSTL) قد حصدت اعترافاً في قائمة Newsweek الأولى America’s Greatest Companies 2025. الشركة المتخصصة في الاختبارات الجزيئية المبتكرة لعناية المرضى اختُيرت من بين 650 شركة أمريكية بناءً على أربعة معايير رئيسية: القوة المالية، تفاني القوى العاملة، الابتكار، والالتزام بالاستدامة البيئية وأخلاقيات الشركات.
شمل عملية التقييم مراجعات للشركة والتقارير SEC وبيانات USPTO ومصادر من طرف ثالث لتقييم أداء الشركة بشكل موضوعي. المؤسس والرئيس التنفيذي Derek Maetzold أبرز نهج «الناس أولا»، مشيراً إلى تركيزهم على تطوير اختبارات جزيئية رائدة وتعزيز ثقافة مؤسسية مبتكرة.
Castle Biosciences（纳斯达克股票代码：CSTL） 已入选 Newsweek 的首个 America's Greatest Companies 2025 榜单。该公司专注于为患者护理提供创新的分子检测，凭借财务实力、员工敬业度、创新及对环境可持续性和企业道德的承诺这四个关键标准，在美国650家企业中脱颖而出。
评估过程包括对公司进行审查、SEC 文件、USPTO 数据及第三方来源的核查，以客观评估企业绩效。首席执行官 Derek Maetzold 强调“以人为本”的理念，强调他们专注于开发前沿分子检测并促进创新的企业文化。
- None.
- None.
FRIENDSWOOD, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has been included in the inaugural 2025 America’s Greatest Companies list, published by Newsweek. The ranking honors 650 U.S. companies demonstrating strong performance across four key pillars: financial strength, workforce dedication, innovation, and commitment to environmental sustainability and corporate ethics.
“This recognition from Newsweek underscores the power of our commitment to ‘put people first' in everything we do, from pioneering molecular tests that may improve patient outcomes, to building a culture that inspires innovation and excellence,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “We’re proud that our dedication to advancing patient care resonates across all facets of our business.”
Evaluations were based on company reviews, filings with the U.S. Securities and Exchange Commission (SEC) and Patent and Trademark Office (USPTO), and third-party data sources to provide an objective measure of corporate performance.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
What recognition did Castle Biosciences (CSTL) receive from Newsweek in 2025?
What criteria were used to evaluate Castle Biosciences for Newsweek's 2025 recognition?
Who is the CEO of Castle Biosciences (CSTL) in 2025?
What is Castle Biosciences' main business focus?
